REGENERON PHARMACEUTICALS
REGENERON PHARMACEUTICALS/ US75886F1075 /
REGN
|
2024-12-20 5:32:12 PM
|
Chg.
+1.80
|
Volume |
Bid5:32:12 PM |
Ask5:32:12 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
681.20EUR
|
+0.26%
|
0
Turnover: - |
-Bid Size: - |
-Ask Size: - |
73.96 bill.EUR |
- |
- |
Fundamentals
| |
FY 2023 |
Growth (1Y) |
| Per Share |
|
| Earnings per Share: |
37.05 USD |
-8.54% |
| EPS Diluted: |
34.77 USD |
-9.03% |
| Revenues per Share: |
121.52 USD |
7.32% |
| Book Value per Share: |
240.62 USD |
14.14% |
| Cash Flow per Share: |
42.56 USD |
-8.76% |
| Dividend per Share: |
- USD |
- |
| Total |
in mill. |
|
| Revenues: |
13,117.20 USD |
7.76% |
| Net Income: |
3,953.60 USD |
-8.87% |
| Operating Cash Flow: |
4,594.00 USD |
- |
| Cash and Cash Equivalents: |
2,730.00 USD |
- |
Valuation Ratios
| |
Current |
Latest FY* |
| P/E Ratio: |
18.94 |
23.71 |
| P/S Ratio: |
5.78 |
7.23 |
| P/BV ratio: |
2.92 |
3.65 |
| P/CF Ratio: |
16.49 |
20.64 |
| PEG: |
-2.22 |
-2.78 |
| Earnings Yield: |
5.28% |
4.22% |
| Dividend Yield: |
- |
- |
| Market Capitalization |
|
| Market Capitalization: |
73.96 bill. EUR |
85.87 bill. EUR |
| Free Float Market Cap.: |
- EUR |
- EUR |
| Market Cap. / Employee: |
- EUR |
- EUR |
| Shares Outstanding: |
108.07 mill. |
|
Profitability
| Gross Profit Margin: |
86.16% |
| EBIT Margin: |
30.85% |
| Net Profit Margin: |
30.14% |
| Return on Equity: |
15.22% |
| Return on Assets: |
11.95% |
Financial Strength
| Liquidity I / Cash Ratio: |
0.80% |
| Liquidity II / Quick Ratio: |
2.45% |
| Liquidity III / Current Ratio: |
5.69% |
| Debt / Equity Ratio: |
0.10% |
| Dynam. Debt / Equity Ratio: |
154.70% |
Efficiency
| Employees: |
- |
| Personal Expenses / Employee: |
- USD |
| Revenues / Employee: |
- USD |
| Net Income / Employee: |
- USD |
| Total Assets / Employee: |
- USD |
| * Fiscal Year End: |
2023-12-31 |
| Accounting Standard: |
US GAAP |
